Perfomance Q1 2017:
In Q1 2017, the blog portfolio gained +9,03% (including dividends, no taxes) against 7,77% for the Benchmark (Eurostoxx50 (Perf.Ind) (25%), Eurostoxx small 200 (25%), DAX (30%), MDAX (20%)). Since inception, the score is now +156,8% vs. 74,7% for the benchmark. The full details (and graph) as always on the performance page.
Some other funds that I follow have performed as follows in Q1 2017:
Partners Fund TGV: +10,88%
Squad European Convictions +8,81%
Ennismore European Smaller Cos 2,04% (in EUR)
Frankfurter Aktienfonds für Stiftungen +5,06%
Evermore Global Value +7,03%
Greiff Special Situation +4,13%
Flight Centre, the Australian based travel company is a company which is on 2 to do lists of mine: The Australian list as well the travel series list. By chance I discovered that there is a book about Flight Centre. I decided to kick-off the analysis with this book review as part 1 of a Flight Centre analysis.
The book covers the complete story of Flight Centre and its founders from the start in 1973 until 2013 and was written by an “insider”, a former employee who worked as head of the UK operations.
Topdanmark – The Danish Cannibal
Topdanmark, a local Danish Insurance company has been on my extended “to do” list for a long time for 2 reasons: It is the second most profitable European insurance company after Admiral (based on ROE) and as Charlie Munger would call it a “true Cannibal”.
Those are some selected numbers from Topdanmark over the last 18 years:
The author of the book is Nils Kröner, a German who among others worked as consultant at McKinsey, at Barclays and for AKO capital before he became professor.
The book has been written following the big financial crisis and starts with a review about what went wrong in general.
Then he introduces the “7 deadly sins of banking” that contributed in his opinion to the banking crisis which are:
Disclaimer: This is not investment advice. please do your own research !!!
Stada is a company I had been looking at many times in the past. A business which in principle is quite good (Generics and OTC drugs) but the company was run by a long time CEO who acted as it was his own company without owning a single share. He paid himself huge salaries, employed his son in a non-sensical but highly paid job, the company afforded itself a huge corporate center and so on. As a result, the company created little to no shareholder value in the 10 years up to mid 2016. As a comparison, the 10 year return of Stada until 03/2016 was only around 1,8% p.a. compared to 7,5 % p.a. for the MSCI Europe health care index, a significant underperformance.
Then however something happened which is still very rare in Germany: A local activist investor (Active Ownership Capital) and some other funds acquired a significant stake in the company and pushed for change.